Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial
Recursion Pharma, a company backed by Nvidia, has made a significant breakthrough in the field of AI-driven drug discovery. Their experimental oral drug, REC-4881, has shown remarkable results in a clinical trial for familial adenomatous polyposis (FAP), a rare genetic condition that increases the risk of colorectal cancer. In this trial, 9 out of 11 patients experienced a durable reduction in total polyp burden, with an impressive median reduction of 53%, 12 weeks after discontinuing therapy.
This achievement marks a pivotal moment for Recursion Pharma, as it is the first clinical validation of their AI platform. Incoming CEO Najat Khan expressed her excitement, stating, 'This is the first clinical validation of Recursion's AI platform, where we garnered unbiased insights to know that this molecule could work in this disease and now proving it in patients with this latest data.'
The use of AI in drug development is gaining traction, with experts predicting a significant reduction in timelines and costs, potentially halving them in the next few years. This technology also aims to minimize animal testing, which is a crucial step towards more ethical and efficient drug discovery. Khan added, 'We're one of the first to show these green shoots of proof points... it's really a good sort of arc in terms of going from discovery AI to the clinic.'
The initial data, released in May, demonstrated a 43% reduction in polyp burden at 13 weeks of treatment in six patients. Recursion Pharma is now expanding its study to include a broader population of patients aged 18 and above, and they plan to engage with the U.S. health regulator in the first half of 2026 to define a potential registration pivotal study pathway.
This breakthrough highlights the potential of AI in revolutionizing the pharmaceutical industry, offering a more efficient and effective approach to drug development and treatment.
